Geron to Participate in Stifel 2022 Healthcare Conference

Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) announced that CEO John A. Scarlett will participate in a fireside chat at the Stifel 2022 Healthcare Conference on November 15, 2022, at 10:55 a.m. ET in New York City. The session will be accessible via a webcast on Geron's Investor Relations website, with an archive available for 30 days post-event. Geron is focused on developing treatments for hematologic malignancies, with ongoing Phase 3 trials for its telomerase inhibitor, imetelstat, targeting lower risk myelodysplastic syndromes and relapsed/refractory myelofibrosis.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Stifel 2022 Healthcare Conference in New York City on Tuesday, November 15, 2022 at 10:55 a.m. ET.

A webcast of the presentation will be available through the Investor Relations section of Geron’s website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Our first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease. Geron currently has two Phase 3 pivotal clinical trials underway evaluating imetelstat in lower risk myelodysplastic syndromes (LR MDS), and in relapsed/refractory myelofibrosis (MF). To learn more, visit www.geron.com or follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005249/en/

Aron Feingold

Investor and Media Relations

investor@geron.com

media@geron.com

Source: Geron Corporation

FAQ

When is Geron's presentation at the Stifel 2022 Healthcare Conference?

Geron's presentation is scheduled for November 15, 2022, at 10:55 a.m. ET.

Where will the fireside chat featuring John A. Scarlett take place?

The fireside chat will take place in New York City.

How can I access the webcast of Geron's presentation?

The webcast will be available through the Investor Relations section of Geron's website.

What is the focus of Geron Corporation's clinical trials?

Geron's clinical trials focus on treatments for hematologic malignancies, specifically evaluating imetelstat.

What types of conditions are being targeted in Geron's Phase 3 trials?

The Phase 3 trials are targeting lower risk myelodysplastic syndromes and relapsed/refractory myelofibrosis.